Table 3.

Comparison of phase I designs under dose-toxicity Scenario 2.

Dose	DLT rate	Designs
		3 + 3	3 + 3@9,2	CS(40; 3,6,9)	CS(25; 5,11)	CS(35; 2,6)	CS(50; 1,3,5)	CS(50)	mTPI	mTPI2	CRM
Proportion of recommended dose (MTD) dose levels (%)
0		3	3	3	9	2	0	0	0	0	0
1	0.05	10	13	9	24	8	2	2	1	0	0
2	0.10	18	22	16	31	14	4	4	7	5	3
3	0.15	21	24	19	23	22	6	6	20	21	9
4	0.20	20	21	21	10	22	9	10	29	28	19
5	0.25	18	13	20	3	19	17	21	28	28	32
6	0.35	9	4	11	0	11	31	36	14	17	29
7	0.50	2	0	1	0	2	26	20	1	2	8
8	0.75	0	0	0	0	0	4	1	0	0	0
9	0.90	0	0	0	0	0	0	0	0	0	0
Proportion of patients treated (%)
1	0.05	24	23	21	38	18	9	7	18	17	7
2	0.10	23	23	22	31	21	10	8	23	23	7
3	0.15	20	21	20	20	21	12	10	25	25	10
4	0.20	15	16	17	8	18	13	12	20	20	17
5	0.25	10	10	12	3	13	15	17	11	11	25
6	0.35	5	5	6	0	7	17	22	4	4	20
7	0.50	2	1	2	0	2	15	17	0	0	12
8	0.75	0	0	0	0	0	6	5	0	0	3
9	0.90	0	0	0	0	0	1	1	0	0	0
Average number of patients		18.7	23.3	24.9	24.6	17.7	15.6	22.6	21.0	21.0	21.0
Percent toxicity (%)		18.1	17.5	17.2	12.9	18.4	30.5	31.3	14.8	14.8	27.5